NEW YORK, August 11, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Brookdale Senior Living Inc. (NYSE: BKD),
Envision Healthcare Holdings Inc. (NYSE: EVHC), BioScrip Inc.
(NASDAQ: BIOS), Perrigo Company PLC (NYSE: PRGO) and Neurocrine
Biosciences Inc. (NASDAQ: NBIX). Free research report on Brookdale
Senior Living can be accessed at
https://www.EquityResearchInstitute.com/reports?keyword=BKD. On
Monday, August 10, 2015, the NASDAQ
Composite ended at 5,101.80, up 1.15%, the Dow Jones Industrial
Average advanced 1.39%, to finish the day at 17,615.17 and the
S&P 500 closed at 2,104.18, up 1.28%. The gains were broad
based as all the sectors ended the session in positive. Register
for your complimentary reports at the links given below.
Brookdale Senior Living Inc.'s stock edged 0.14% higher, to
close the day at $29.16. The stock
recorded a trading volume of 2.88 million shares, above its three
months average volume of 2.34 million shares. Over the last one
month and over the past three months, Brookdale Senior Living
Inc.'s shares have declined 13.88% and 19.07%, respectively.
Furthermore, the stock has lost 20.48% since the start of this
year. The company's shares are trading 15.50% below their 50-day
moving average. Additionally, Brookdale Senior Living Inc. has a
Relative Strength Index (RSI) of 18.85. Sign up and read the free
notes on BKD at:
https://www.EquityResearchInstitute.com/reports?keyword=BKD
On Monday, shares in Envision Healthcare Holdings Inc. recorded
a trading volume of 1.58 million shares, lower than their three
months average volume of 1.75 million shares. The stock ended the
day 0.63% higher at $44.38. Shares of
the company traded at a PE ratio of 44.83. Envision Healthcare
Holdings Inc.'s stock has surged 13.85% in the last one month,
22.94% in the previous three months and 27.93% on YTD basis. The
company is trading above its 50-day and 200-day moving averages by
12.18% and 19.84%, respectively. Furthermore, shares of Envision
Healthcare Holdings Inc. have an RSI of 71.07. The complimentary
notes on EVHC can be downloaded in PDF format at:
https://www.EquityResearchInstitute.com/reports?keyword=EVHC
BioScrip Inc.'s stock plummeted 22.39%, to close Monday's
session at $2.08. The stock recorded
a trading volume of 4.20 million shares, much above its three
months average volume of 1.19 million shares. Over the last one
month and the previous three months, BioScrip Inc.'s shares have
declined 31.58% and 47.61%, respectively. Additionally, the stock
has plummeted 70.24% since the start of this year. The company is
trading 35.67% and 57.51% below its 50-day and 200-day moving
averages, respectively. Furthermore, BioScrip Inc.'s stock has an
RSI of 27.16. Register for free on Equity Research Institute and
access the latest research on BIOS at:
https://www.EquityResearchInstitute.com/reports?keyword=BIOS
Perrigo Co. PLC's stock finished Monday's session 1.99% higher
at $193.99. A total of 0.77 million
shares were traded, which was below its three months average volume
of 1.15 million shares. Over the last one month and the previous
three months, Perrigo Co. PLC's shares have advanced 7.26% and
0.28%, respectively. Additionally, the stock has gained 16.22%
since the beginning of 2015. The company's shares are trading above
their 50-day and 200-day moving averages by 3.14% and 12.33%,
respectively. Perrigo Co. PLC's stock traded at a PE ratio of
129.33 and has an RSI of 60.12. The complete research on PRGO is
available for free at:
https://www.EquityResearchInstitute.com/reports?keyword=PRGO
On Monday, shares in Neurocrine Biosciences Inc. ended the
session 0.47% lower at $46.25. The
stock reported a trading volume of 0.63 million shares, below its
three months average volume of 0.87 million shares. Although,
Neurocrine Biosciences Inc.'s shares have lost 3.97% in the last
one month, it has surged 16.70% in the previous three months and
107.03% on YTD basis. The company is trading 28.92% above its
200-day moving average. Moreover, shares of Neurocrine Biosciences
Inc. have an RSI of 40.19. Free in-depth research on NBIX is
available at:
https://www.EquityResearchInstitute.com/reports?keyword=NBIX
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com